{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104938",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104938",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for acenocoumarol and VKORC1",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA452632",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA452632",
    "name" : "acenocoumarol"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA133787052",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA133787052",
    "symbol" : "VKORC1",
    "name" : "vitamin K epoxide reductase complex, subunit 1"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>While VKORC1 genotype has been found to contribute to acenocoumarol dose variability, there are no dosing recommendations at this time. Check INR more frequently in patients with the AA genotype at <a href=\"/rsid/rs9934438\">rs9934438</a>.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on VKORC1 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They found that VKORC1 genotype contributes to dose variability.  However, they make no dosing recommendations at this time \"because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.\"</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Genotype </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a> AG </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5</td></tr><tr></tr><tr><td> VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a> AA </td><td> Check INR more frequently. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5</td></tr><tr></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li></ul>"
}